文献速递银屑病与炎症性皮肤病

Certolizumab治疗银屑病和银屑病关节炎:意大利多中心真实世界研究

Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-06-26

该回顾性研究纳入意大利11个中心的153例银屑病和银屑病关节炎患者,接受certolizumab皮下注射至52周。结果显示PASI评分自基线平均下降12周4.45、24周6.30、52周7.58(均P<0.001),24周和52周分别有69.6%和83.3%患者PASI≤3,关节和指甲评分及疼痛VAS也显著改善。

要点

  • Certolizumab在真实世界中显著改善银屑病和银屑病关节炎患者的皮肤与关节症状。
  • 治疗24周和52周时分别有69.6%和83.3%的患者达到PASI≤3。
  • 银屑病病程、基线PASI、mNAPSI和疼痛VAS可预测第12周PASI改善。

核心结论

  • Certolizumab在真实世界中对银屑病和银屑病关节炎患者显示出令人鼓舞的疗效。

研究设计与样本

  • 回顾性研究,涉及意大利11个中心,纳入153例银屑病和银屑病关节炎患者,接受皮下certolizumab(400 mg负荷剂量于0、2、4周,随后200 mg每2周)治疗至52周。

主要发现

  • Certolizumab使平均PASI评分自基线下降:第12周4.45、第24周6.30、第52周7.58(所有P<0.001)。
  • 第24周和第52周分别有69.6%和83.3%的患者PASI评分≤3。
  • DAS44-ESR、压痛关节数、肿胀关节数、mNAPSI评分和疼痛VAS在各时间点均较基线显著改善。
  • C反应蛋白水平在治疗期间下降,第24周时显著。
  • 多变量分析显示,银屑病病程、基线PASI、mNAPSI和疼痛VAS评分可预测第12周PASI评分的改善。

关键数值与推荐

  • 主要结局包括PASI和mNAPSI评分自基线的平均变化,以及达到PASI 75%、90%或100%改善的患者比例。
  • 其他终点包括DAS44-ESR、压痛关节数、肿胀关节数、疼痛VAS、炎症标志物和生活质量。

临床怎么用

  • Certolizumab可作为银屑病和银屑病关节炎患者的治疗选择,真实世界数据支持其有效性。
  • 银屑病病程、基线PASI、mNAPSI和疼痛VAS评分有助于预测早期PASI改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Certolizumab, a pegylated tumour necrosis factor-α inhibitor, reduced disease activity in randomized trials of patients with psoriasis and psoriatic arthritis. Real-life data are missing. OBJECTIVE: To confirm the effectiveness and safety of certolizumab in patients with psoriasis and psoriatic arthritis in routine clinical practice. METHODS: In this retrospective study involving 11 Italian sites, patients with psoriasis and psoriatic arthritis received subcutaneous certolizumab (400 mg loading dose at 0, 2 and 4 weeks, followed by 200 mg every 2 weeks) for up to 52 weeks. Primary outcomes included mean change from baseline in Psoriasis Area and Severity Index (PASI) and modified Nail Psoriasis Severity Index (mNAPSI) scores, and the proportion of patients achieving a 75%, 90% or 100% reduction in PASI score. Other endpoints included Disease Activity Score computed on 44 joints correlated with the erythrocyte sedimentation rate during the first hour (DAS44-ESR), Tender Joint Count (TJC), Swollen Joint Count (SJC), pain [visual analogue scale (VAS) score], inflammatory markers and quality of life (QOL). RESULTS: In the study were enrolled 153 patients (mean age: 55 years). Certolizumab reduced the mean PASI score from baseline by 4.45, 6.30 and 7.58 at weeks 12, 24 and 52, respectively (P < 0.001 for all). At weeks 24 and 52, 69.6% and 83.3% of patients had a PASI score ≤3. DAS44-ESR, TJC, SJC and mNAPSI scores, and pain VAS were also all significantly improved from baseline at each time point. C-reactive protein levels decreased during treatment, being significant at week 24. On multivariate analysis, psoriasis duration, baseline PASI, mNAPSI and pain VAS scores were found to be predictive of the improvement in PASI score at week 12. CONCLUSION: Certolizumab displayed also in the real-life encouraging results in both psoriasis and psoriatic arthritis patients.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Dattola A, Balato A, Megna M, et al. Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study. J Eur Acad Dermatol Venereol. 2020. PMID: 32401377. doi:10.1111/jdv.16606

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。